by CheckRare Staff | Feb 10, 2024
Jatin Shah, MD, PhD, of Sumitomo Pharma, discusses two treatments in Phase 1 trials for myelofibrosis and acute myeloid leukemia. Jatin Shah, MD, PhD, of Sumitomo Pharma, discusses two treatments in Phase 1 trials for myelofibrosis and acute myeloid...
by CheckRare Staff | Feb 9, 2024
Steven Pipe, MD, of the University of Michigan, discusses the results of HAVEN 7, a Phase 3 trial testing the efficacy and safety of emicizumab to prevent bleeding episodes in patients under 12 months of age with hemophilia A. Hemophilia A is a...
by CheckRare Staff | Feb 7, 2024
Giacomo Chiesi, Head of Chiesi Global Rare Diseases and co-author of the report “Rare Disease Burden of Care and the Economic Impact of Citizens in Germany, France, and Italy”, discusses report in detail. There are an estimated 35-36 million...
by CheckRare Staff | Feb 6, 2024
Kim Smith-Whitley, MD, chief medical officer for Real-World Evidence, Patient Advocacy, and External Collaborations at Pfizer and pediatric hematologist at the Children’s Hospital of Philadelphia, discusses recent advances in sickle cell disease treatment. ...
by CheckRare Staff | Feb 5, 2024
Judith Luker, head of Patient Engagement, Epilepsy and Rare Syndromes (Europe) at UCB Pharma, discusses the sudden unexpected death in epilepsy (SUDEP) communication gap and the importance of physician-patient conversations. SUDEP is the unexpected death...
